Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Boston Scientific Corp., consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

US$ in millions

	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018
Current debt obligations	510)	20)	20)	170)	238)	261)	261)	262)	13)	13)	11)	254)	1,004)	1,416)	1,297)	1,949)	1,638)	2,253)	1,820)	1,685)	962)
Accounts payable	868)	862)	803)	732)	696)	794)	674)	689)	615)	513)	452)	408)	605)	542)	512)	524)	498)	349)	453)	403)	404)
Accrued expenses	1,918)	2,160)	1,974)	2,197)	2,306)	2,436)	2,418)	2,442)	2,060)	2,197)	2,195)	1,718)	1,562)	2,109)	1,932)	1,932)	1,963)	2,246)	2,469)	2,266)	2,447)
Other current liabilities	787)	761)	752)	784)	1,035)	783)	669)	680)	705)	958)	644)	728)	805)	799)	513)	445)	380)	412)	340)	399)	1,175)
Current liabilities	4,083)	3,803)	3,549)	3,883)	4,275)	4,274)	4,022)	4,073)	3,393)	3,681)	3,302)	3,108)	3,976)	4,866)	4,254)	4,850)	4,479)	5,260)	5,082)	4,753)	4,988)
Long-term debt	8,495)	8,915)	8,564)	8,802)	9,067)	8,804)	8,824)	8,847)	9,082)	9,130)	9,325)	9,278)	9,331)	8,592)	9,590)	7,591)	7,590)	4,803)	4,806)	4,808)	4,803)
Deferred income taxes	210)	144)	278)	265)	261)	310)	274)	115)	336)	330)	522)	585)	589)	595)	807)	416)	441)	328)	428)	364)	128)
Other long-term liabilities	1,995)	2,034)	1,916)	1,988)	1,999)	2,220)	2,296)	2,191)	2,370)	2,310)	2,132)	2,236)	2,413)	2,635)	2,406)	2,027)	2,059)	1,882)	1,774)	1,946)	2,253)
Long-term liabilities	10,700)	11,093)	10,758)	11,055)	11,327)	11,334)	11,394)	11,153)	11,788)	11,770)	11,979)	12,099)	12,333)	11,822)	12,803)	10,034)	10,090)	7,013)	7,008)	7,118)	7,184)
Total liabilities	14,783)	14,896)	14,307)	14,938)	15,602)	15,608)	15,416)	15,226)	15,181)	15,451)	15,281)	15,207)	16,309)	16,688)	17,057)	14,884)	14,569)	12,273)	12,090)	11,871)	12,172)
Preferred stock, $0.01 par value	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Common stock, $0.01 par value	17)	17)	17)	17)	17)	17)	17)	17)	17)	17)	17)	17)	16)	16)	16)	16)	16)	16)	16)	16)	16)
Treasury stock, at cost	(2,251)	(2,251)	(2,251)	(2,251)	(2,251)	(2,251)	(2,251)	(2,251)	(2,251)	(2,251)	(1,717)	(1,717)	(1,717)	(1,717)	(1,717)	(1,717)	(1,717)	(1,717)	(1,717)	(1,717)	(1,717)
Additional paid-in capital	20,356)	20,288)	20,218)	20,102)	20,043)	19,985)	19,930)	19,817)	19,749)	19,731)	19,687)	19,590)	17,589)	17,561)	17,511)	17,423)	17,375)	17,347)	17,304)	17,231)	17,185)
Accumulated deficit	(450)	(750)	(876)	(1,050)	(1,296)	(1,392)	(1,473)	(1,878)	(2,050)	(2,378)	(2,574)	(2,405)	(2,252)	(2,253)	(6,249)	(6,375)	(6,528)	(6,953)	(7,339)	(7,770)	(8,326)
Accumulated other comprehensive income (loss), net of tax	178)	269)	532)	433)	222)	263)	238)	237)	254)	207)	151)	131)	168)	270)	138)	78)	87)	33)	25)	(16)	(128)
Stockholders’ equity	17,850)	17,573)	17,640)	17,251)	16,735)	16,622)	16,461)	15,942)	15,719)	15,326)	15,564)	15,616)	13,804)	13,877)	9,699)	9,425)	9,233)	8,726)	8,289)	7,744)	7,030)
Noncontrolling interests	259)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)	—)
Total equity	18,109)	17,573)	17,640)	17,251)	16,735)	16,622)	16,461)	15,942)	15,719)	15,326)	15,564)	15,616)	13,804)	13,877)	9,699)	9,425)	9,233)	8,726)	8,289)	7,744)	7,030)
Total liabilities and equity	32,892)	32,469)	31,947)	32,189)	32,337)	32,230)	31,877)	31,168)	30,900)	30,777)	30,845)	30,823)	30,113)	30,565)	26,756)	24,309)	23,802)	20,999)	20,379)	19,615)	19,202)

The analysis of the quarterly financial data reveals several noteworthy trends in the company’s financial position over the examined periods.

Current Debt Obligations: Current debt obligations showed significant volatility, peaking at 2,253 million USD in December 2018 and then declining sharply to very low levels around 11-20 million USD during the quarters of 2020 and early 2021. A notable increase occurred again in the first quarter of 2023, reaching 510 million USD, indicating a potential increase in short-term borrowings or liquidity needs at that time.
Accounts Payable: Accounts payable displayed a generally upward trend from 404 million USD in March 2018 to 868 million USD by March 2023. Despite fluctuations, the gradual increase suggests growing obligations to suppliers, consistent with expanding operations or purchasing activity.
Accrued Expenses: Accrued expenses declined from approximately 2,447 million USD in March 2018 to a low point of 1,562 million USD by March 2020, followed by a rebound to values exceeding 2,000 million USD in subsequent quarters. The fluctuations may reflect changes in accrued liabilities such as wages, taxes, and other short-term obligations corresponding to operational cycles.
Other Current Liabilities: This category showed irregular movements with a high point near 1,035 million USD in March 2022. The fluctuations within the referenced years indicate adjustments in miscellaneous current liabilities that might be impacted by various short-term financial arrangements or provisions.
Current Liabilities: Overall current liabilities decreased from 4,988 million USD in March 2018 to a trough around 3,108 million USD in March 2020, before rebounding close to 4,083 million USD by March 2023. This pattern aligns with movements in individual current liability components and reflects adaptations in short-term financial obligations likely influenced by market conditions and company operations.
Long-Term Debt: Long-term debt rose substantially from about 4,803 million USD in March 2018 to reach a peak near 9,590 million USD in September 2019. After this peak, it generally trended downward with some fluctuations, settling around 8,495 million USD by March 2023. The increase through 2019 indicates significant long-term financing activity, while the gradual decline in more recent periods suggests debt repayments or refinancing.
Deferred Income Taxes: Deferred income taxes increased from 128 million USD in March 2018 to a high near 807 million USD by September 2019, followed by a steady decline to 210 million USD in March 2023. These changes point to varied tax timing differences affecting the company’s reported deferred tax assets or liabilities over time.
Other Long-Term Liabilities: Other long-term liabilities decreased from 2,253 million USD in March 2018 to a low near 1,916 million USD in September 2022, with some interim fluctuations. This suggests a general reduction in miscellaneous long-term obligations, which could be related to pension liabilities, deferred compensation, or other such accounts.
Long-Term Liabilities: Long-term liabilities rose considerably from approximately 7,184 million USD in March 2018 to a peak above 12,803 million USD in September 2019. Subsequently, there was a downward trend to about 10,700 million USD by March 2023, mirroring the pattern in long-term debt and other long-term liabilities. This reflects changes in long-term financing and non-debt liabilities.
Total Liabilities: Total liabilities increased steadily from 12,172 million USD in March 2018, peaked near 17,057 million USD in July 2019, and then exhibited a gradual decline with fluctuations, ending at 14,783 million USD by March 2023. The trajectory reflects the combined trends seen in current and long-term liabilities.
Common Stock: Common stock value remained relatively stable at around 16-17 million USD throughout the examined period, indicating no major changes in the number of outstanding common shares or par value adjustments.
Treasury Stock: Treasury stock remained steady at approximately -1,717 million USD until late 2019 and then shifted to around -2,251 million USD from late 2020 onward, suggesting increased repurchases or changes in the cost basis of treasury shares during that timeframe.
Additional Paid-In Capital: Additional paid-in capital displayed a steady increase from approximately 17,185 million USD in early 2018 to over 20,356 million USD by March 2023, indicating incremental capital contributions, stock-based compensation, or other equity transactions that increased equity value beyond par.
Accumulated Deficit: Accumulated deficit showed gradual improvement from -8,326 million USD in March 2018 to -450 million USD in March 2023, reflecting a consistent reduction in cumulative losses or a move toward profitability over this period.
Accumulated Other Comprehensive Income (Loss), Net of Tax: This equity component shifted from a negative balance in early 2018 (-128 million USD) to positive values exceeding 500 million USD in late 2022, before settling near 178 million USD in early 2023. The movements indicate fluctuations in items such as foreign currency translation adjustments, unrealized gains/losses, or pension plan adjustments affecting comprehensive income.
Stockholders’ Equity: Stockholders’ equity rose notably from 7,030 million USD in March 2018 to reach approximately 17,850 million USD by March 2023, displaying a positive trend that suggests sustained growth in company net assets, driven by capital increases, improved earnings, and reductions in accumulated deficit.
Total Equity: Total equity trends were consistent with stockholders’ equity, rising from 7,030 million USD to 18,109 million USD over the same period, including the addition of noncontrolling interest which appears only in the last quarter with 259 million USD, indicating a consolidation or acquisition event.
Total Liabilities and Equity: The sum of liabilities and equity showed steady growth from 19,202 million USD in March 2018 to 32,892 million USD by March 2023, demonstrating overall expansion in the company's balance sheet size and capitalization.

In summary, the company experienced substantial growth in equity alongside stabilized common stock levels and increasing paid-in capital. Debt profiles indicate increased leverage around 2019 followed by deleveraging efforts. The significant improvements in accumulated deficit and stockholders’ equity reflect strengthened financial health. Current liabilities showed a decline during early 2020, possibly due to external factors impacting short-term obligations, with a recovery thereafter. Fluctuations in deferred taxes and other liabilities also highlight dynamic tax and long-term liability management.

Download chart

Boston Scientific Corp. (NYSE:BSX)

Balance Sheet: Liabilities and Stockholders’ Equity Quarterly Data

Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data